Celecoxib: A potent cyclooxygenase-2 inhibitor in cancer prevention

Cancer Detection and Prevention

Volumn 28, Issue 2, 2004, Pages 127-142

  Kismet, Kemal ^a   Akay, M Turan ^b   Abbasoǧlu, Osman ^b   Ercan, Aygün ^b  

^a Ankara Research and Training Hospital   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Celecoxib; Chemoprevention; Cyclooxygenase; Non steroidal anti inflammatory drugs

Indexed keywords

EID: 1842531376     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdp.2003.12.005     Document Type: Article

References (168)

1. Dubois R.N., Abramson S.B., Croffrod L.et al. Cyclooxygenase in biology and disease. FASEB J. 12:1998;1063-1073.
2. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:1971;232-235.
3. Needleman P., Isakson P.C. The discovery and function of COX-2. J. Rheumatol. 24(Suppl. 49):1997;6-8.
4. Lipsky P.E. Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? J. Rheumatol. 26(Suppl. 56):1999;25-30.
5. Van Ryn J., Pairet M. Clinical experience with cyclooxygenase-2 inhibitors. Inflamm. Res. 48:1999;247-254.
6. Geis G.S. Update on clinical developments with celecoxib a new specific COX-2 inhibitor: what can we expect? J. Rheumatol. 26(Suppl. 56):1999;31-36.
7. Hawkey C.J. COX-2 inhibitors. Lancet. 353:1999;307-314.
8. Graul A., Martel A.M., Castaner J. Celecoxib. Drugs Future. 22:1997;711-714.
9. Isakson P, Zweifel B, Masferrer J, et al. Specific COX-2 inhibitors: from bench to bedside. In: Vane J, Botting J, editors. Selective COX-2 inhibitors: pharmacology, clinical effects and therapeutic potential. London: William Harvey Press; 1997. p. 127-33.
10. Lipsky P.E., Isakson P.C. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J. Rheumatol. 24:1997;9-14.
11. Penning T.D., Talley J.J., Bertenshaw S.R.et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem. 40:1997;1347-1365.
12. Brooks P.M., Day R.D. COX-2 inhibitors. Med. J. Aust. 173:2000;433-436.
13. Pamham M.J. Inflammation: mechanisms and therapeutics. Drugs News Perspect. 9:1996;631-639.
14. Lanza F.L., Rack M.F. A pilot endoscopy study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastroenterology. 112:1997;A194.
15. Simon L.S., Lanza F.L., Lipsky P.E.et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 41:1998;1591-1602.
16. Mengle-Gaw L., Hubbard R.C., Karim A.et al. A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor. Arthritis Rheumatol. 40(Suppl.):1997;S93.
17. Ault A. First COX-2 inhibitor clears initial FDA hurdle (news: science and medicine). Lancet. 352:1998;1912.
18. Hawkey C.J. NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective. Clin. Exp. Rheumatol. 19(Suppl. 25):2001;S23-S30.
19. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin Exp Rheumatol 2001;19(Suppl 25):S15-22.
20. American Cancer Society Statistics: Cancer. American Cancer Society, Inc., 2003.
21. Smalley W.E., DuBois R.N. Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv. Pharmacol. 39:1997;1-20.
22. Thun M.J., Namboodiri M.M., Heath C.W.J. Aspirin use and reduced risk of fatal colon cancer. N. Eng. J. Med. 325:1991;1593-1596.
23. Thompson H.J., Jiang C., Lu J.et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57:1997;267-271.
24. Hida T., Leyton J., Makheja A.N.et al. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res. 18:1998;775-782.
25. Fukutake M., Nakatsugi S., Isoi T.et al. Supressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2 on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis. 19(11):1998;1939-1942.
26. Binder H.J. Prevention of colorectal cancer: tumor progression, chemoprevention, and COX-2 inhibition (selected summaries). Gastroenterology. 119:2000;267-272.
27. American Cancer Society Statistics: Colorectal cancer. American Cancer Society, Inc., 2003.
28. National Cancer Institute Press Release: annual report shows continuing decline in US cancer incidence and death rates special section focuses on colorectal cancer, 2001.
29. Kune G.A., Kune S., Watson L.F. Colorectal cancer risk, chronic illness, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48:1988;4399-4404.
30. Rosenberg L., Palmer J.R., Zauner A.G.et al. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of the large-bowel cancer. J. Natl. Cancer Inst. 83:1991;355-358.
31. Suh O., Mettlin C., Petrelli N.J. Aspirin use, cancer, and polyps of the large bowel. Cancer (Philadelphia). 72:1993;1171-1177.
32. Greenberg E.R., Baron J.A., Freeman D.H. Jr.et al. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Group. J. Natl. Cancer Inst. 85:1993;912-916.
33. Spagnesi M.T., Tonelli F., Dolara P.et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology. 106:1994;362-366.
34. Narisawa T., Sato M., Tani M.et al. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res. 41:1981;1954-1957.
35. Moorghen M., Ince P., Finney K.J.et al. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J. Pathol. 156:1988;341-347.
36. Reddy B.S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, and non-steroidal anti-inflammatory drugs during different stages of rat colon tumor development. Cancer Res. 47:1987;5340-5346.
37. Rao C.V., Rivenson A., Simi B.et al. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res. 55:1995;1464-1472.
38. DuBois R.N., Tsujii M., Bishop P.et al. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am. J. Physiol. 266:1994;G822-G827.
39. Eberhart C.E., Coffey R.J., Radhika A.et al. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
40. DuBois R.N., Radhika A., Reddy B.S.et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology. 110:1996;1259-1262.
41. Williams C.S., Luongo C., Radhika A.et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 111:1996;1134-1140.
42. Rigas B., Goldman I.S., Levine N. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122:1993;518-523.
43. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell. 87:1996;803-809.
44. Reddy B.S., Rao C.V., Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56:1996;4566-4569.
45. Kawamori T., Rao C.V., Seibert K.et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
46. Fujita T., Matsui M., Takaku K.et al. Size- and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res. 58:1998;4823-4826.
47. Erickson B.A., Longo W.E., Panesar N.et al. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J. Surg. Res. 81:1999;101-107.
48. Reddy B.S., Hirose Y., Lubet R.et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60:2000;293-297.
49. Williams C.S., Watson A.J.M., Sheng H.et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60:2000;6045-6051.
50. Steinbach G., Lynch P.M., Phillips R.K.S.et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Eng. J. Med. 342:2000;1946-1952.
51. Jacoby R.F., Seibert K., Cole C.E.et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. 60:2000;5040-5044.
52. Phillips R.K., Wallace M.H., Lynch P.M.et al. A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 50:2002;857-860.
53. Ritsimaki A., Honkanen N., Jankala H.et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1997;1276-1280.
54. Sawaoka H., Kawano S., Tsuji S.et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 274(6 Pt 1):1998;G1061-G1067.
55. Thun M.J., Calle E.E., Flanders W.D.et al. Aspirin use and risk of fatal cancer. Cancer Res. 53:1993;1322-1327.
56. Funkhouser E.M., Sharp G.B. Aspirin and reduced risk of esophageal carcinoma. Cancer (Philadelphia). 76:1995;1116-1119.
57. Rubio C.A. Antitumoral activity of indomethacin on experimental esophageal tumors. J. Natl. Cancer Inst. 72:1984;705-707.
58. Rubio C.A. Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer (Philadelphia). 58:1986;1029-1031.
59. Zimmermann K.C., Sarbia M., Weber A.A.et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:1999;198-204.
60. Koga H., Sakisaka S., Ohishi M.et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Hepatology. 29:1999;688-696.
61. Shiota G., Okubo M., Noumi T.et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepato-Gastroenterology. 46:1999;407-412.
62. Kern M.A., Schubert D., Sahi D.et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology. 36:2002;885-894.
63. Wu G.S., Zou S.Q., Liu Z.R.et al. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J. Gastroenterol. 9:2003;1302-1306.
64. Tucker O.N., Dannenberg A.J., Yang E.K.et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59:1999;987-990.
65. Wenger F.A., Kilian M., Bisevac M.et al. Effects of celebrex and zyflo on liver metastasis and lipid peroxidation in pancreatic cancer in Syrian hamsters. Clin. Exp. Metast. 19:2002;681-687.
66. Crane C.H., Mason K., Janjan Na.et al. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am. J. Clin. Oncol. 26:2003;S81-S84.
67. Duperron C., Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis (London). 18:1997;1001-1006.
68. Hida T., Yatabe Y., Achiwa H.et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:1998;3761-3764.
69. Wolff H., Saukkonen K., Anttila S.et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001.
70. Diperna C.A., Bart R.D., Sievers E.M.et al. Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J. Thorac. Cardiovasc. Surg. 126:2003;1129-1133.
71. Liu W., Chen Y., Wang W.et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am. J. Clin. Oncol. 26:2003;S103-S109.
72. Altorki N.K., Keresztes R.S., Port J.L.et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2645-2650.
73. American Cancer Society Statistics: Breast Cancer. American Cancer Society, Inc., 2003.
74. 2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br. J. Cancer. 72:1995;1412-1419.
75. Tan W.C., Privett O.S., Goldyne M.E. Studies of prostaglandins in rat mammary tumors induced by 7,12- dimethylbenzanthracene. Cancer Res. 34:1974;3229-3231.
76. Rolland P.H., Martin P.M., Jacquemier J.et al. Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst. 64:1980;1061-1070.
77. Fulton A.M., Heppner G.H. Relationship of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinoma. Cancer Res. 45:1985;4779-4784.
78. 2 content. J. Natl. Cancer Inst. 69:1982;443-446.
79. Connolly J.M., Liu X-H, Rose D.P. Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor. Nutr. Cancer. 25:1996;231-240.
80. Liu X-H, Rose D.P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 56:1996;5125-5127.
81. Harris R.E., Namboodiri K.K., Steilman S.D.et al. Breast cancer and NSAID use: heterogenity of effect in a case-control study. Prev. Med. 24:1995;119-120.
82. Harris R.E., Namboodiri K.K., Farrar W.B. Non-steroidal anti-inflammatory drugs and breast cancer. Epidemiology. 7:1996;203-205.
83. Harris R.E., Namboodiri K.K., Farrar W.B. Epidemiological study of non-steroidal anti-inflammatory drugs and breast cancer. Oncol. Rep. 2:1995;591-592.
84. Robertson F.M., Parrett M.L., Joarder F.S.et al. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett. 122:1998;165-175.
85. McCormick D.L., Madigan M.J., Moon R.C. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. 45:1985;1803-1808.
86. Alshafie G.A., Harris R.E., Abou-Issa H.et al. Chemopreventive effects of ibuprofen and 4-HPR in the DMBA rat mammary tumor model. Anticancer Res. 19:1999;1-6.
87. Harris R.E., Alshafie G.A., Abou-Issa H.et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;2101-2103.
88. Alshafie G.A., Abou-Issa H.M., Seibert K.et al. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol. Rep. 7:2000;1377-1381.
89. Kundu N., Fulton A.M. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 62:2002;2343-2346.
90. 2 synthesis by human epidermoid carcinoma cells. J. Invest. Dermatol. 101:1993;528-531.
91. Vanderveen E.E., Grekin R.C., Swanson N.A.et al. Arachidonic acid metabolites in cutaneous carcinomas. Arch. Dermatol. 122:1986;407-412.
92. Klapan I. Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer. J. Cancer Res. Clin. Oncol. 118:1986;308-313.
93. Buckman S.Y., Gresham A., Hale P.et al. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis. 19:1998;723-729.
94. Chan G., Boyle J.O., Yang E.K.et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:1999;991-994.
95. Fischer S.M., Lo H.H., Gordon G.B.et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinogen. 28:1999;231-240.
96. Pentland A.P., Schoggins J.W., Scott G.A.et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 20:1999;1939-1944.
97. Wilgus T.A., Koki A.T., Zweifel B.S.et al. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol. Carcinogen. 38:2003;49-58.
98. Wilgus T.A., Koki A.T., Zweifel B.S.et al. Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol. Carcinogen. 38:2003;33-39.
99. American Cancer Society Statistics: Prostate cancer. American Cancer Society, Inc., 2003.
100. Yoshimura R., Sano H., Masuda C.et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 89:2000;589-596.
101. Hsu A.L., Ching T.T., Wang D.S.et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275:2000;11397-11403.
102. Grubbs C.J., Lubet R.A., Koki A.T.et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:2000;5599-5602.
103. Wang Z., Polavaram R., Shapshay S.M. Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. Cancer Lett. 198:2003;53-58.
104. Wang Z., Fuentes C.F., Shapshay S.M. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope. 112:2002;839-843.
105. Dickens D.S., Cripe T.P. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J. Pediatr. Hematol. Oncol. 25:2003;709-714.
106. Ferrandina G., Ranelletti F.O., Legge F.et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin. Cancer Res. 9:2003;4324-4331.
107. Prescott S.M., White R.L. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell. 87:1996;783-786.
108. Piazza G.A., Rahm A.L.K., Krutzsch M.et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55:1995;3110-3116.
109. Piazza G.A., Alberts D.S., Hixson L.J.et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57:1997;2909-2915.
110. Reddy B.S., Kawamori T., Lubet R.A.et al. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res. 59:1999;3387-3391.
111. Mahmoud N.N., Boolbol S.K., Dannenberg A.J.et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis. 19:1998;87-91.
112. Elder D.J., Halton D.E., Hague A.et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 3:1997;1679-1683.
113. Hanif R., Pittas A., Feng Y.et al. Effects of non-steroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52:1996;237-245.
114. Zhang X., Morham S.G., Langenbach R.et al. Malignant transformation and antineoplastic actions of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190:1999;451-460.
115. Ahnen D.J. Colon cancer prevention by NSAIDs: what is the mechanism of action? Eur. J. Surg. Suppl. 582:1998;111-114.
116. Charalambous D., Skinner S.A., O'Brein P.E. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat. J. Gastroenterol. Hepatol. 13:1998;1195-1200.
117. Simmons D.L., Botting R.M., Robertson P.M.et al. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to non-steroid anti-inflammatory drugs. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3275-3280.
118. He T.C., Chan T.A., Vogelstein B.et al. PPARδ is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell. 99:1999;335-345.
119. Shiff S.J., Qiao L., Tsai L.et al. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96:1995;491-503.
120. Elder D.J.E., Hague A., Hicks D.J.et al. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res. 56:1996;2273-2276.
121. Pasricha P.J., Bedi A., O'Connor K.et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology. 109:1995;994-998.
122. Hara A., Yoshimi N., Niwa M.et al. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res. 88:1997;600-604.
123. 2 in human colon cancer cells. Cancer Res. 58:1998;362-366.
124. Liu X.H., Yao S., Kirschenbaum A.et al. NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates Bcl-2 expression in LNCaP cells. Cancer Res. 58:1998;4245-4249.
125. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 83:1995;493-501.
126. Takahashi M., Fukutake M., Yokota S.et al. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase-2. J. Cancer Res. Clin. Oncol. 122:1996;219-222.
127. Grösch S., Tegeder I., Niederberger E.et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15:2001;2742-2744.
128. Brown W.A., Skinner S.A., Malcontenti-Wilson C.et al. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase-1 or cyclooxygenase-2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut. 48:2001;660-666.
129. Chan T.A., Morin P.J., Vogelstein B.et al. Mechanisms underlying non-steroidal anti-inflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 95:1998;681-686.
130. Tang D.G., Chen Y.Q., Honn K.V. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 93:1996;5241-5246.
131. Lin M.T., Lee R.C., Yang P.C.et al. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL 1.0 cells. J. Biol. Chem. 276:2001;48997-49002.
132. Brown W.A., Skinner S.A., Vogiagis D.et al. Inhibition of β-catenin translocation in rodent colorectal tumors. Dig. Dis. Sci. 46:2001;2314-2321.
133. Arico S., Pattingre S., Bauvy C.et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 277:2002;27613-27621.
134. 2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem. J. 366:2002;831-837.
135. Narko K., Ristimaki A., MacPhee M.et al. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J. Biol. Chem. 272:1997;21455-21460.
136. 2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172:1983;214-218.
137. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
138. Tsujii M., Kawano S., Tsuji S.et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
139. Seed M.P., Brown J.R., Freemantle C.N.et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res. 57:1997;1625-1629.
140. Masferrer J.L., Leahy K.M., Koki A.T.et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
141. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30:2000;3-21.
142. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
143. Sheng G.G., Shao J., Sheng H.et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology. 113:1997;1883-1891.
144. Subbaramaiah K., Telang N., Ramonetti J.T.et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56:1996;4424-4429.
145. Cormier R.T., Hong K.H., Halberg R.B.et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 17:1997;88-91.
146. min-induced intestinal neoplasia. Cell. 81:1995;957-966.
147. Williams C.S., Shattuck-Brandt R.L., DuBois R.N. The role of COX-2 in intestinal cancer. Exp. Opin. Invest. Drugs. 8:1999;1-12.
148. 2 gene in human and rat: choromosomal localization and polymorphic markers. Genomics. 26:1995;138-141.
149. 2 (PLA 2G 2A) expression status in colorectal carcinoma derived cell lines in normal colonic mucosa. Oncogene. 17:1998;20009-20012.
150. 2 inhibitors on proliferation and apoptosis of murine intestinal cells. J. Surg. Res. 84:1999;51-56.
151. Subbaramaiah K., Altorki N., Chung W.J.et al. Inhibition of cyclooxygenase-2 gene expression by p53. Biol. Chem. 274:1999;10911-10915.
152. Ananthaswamy H.N., Ullrich S.E., Mascotto R.E.et al. Inhibition of solar stimulator-induced p53 mutations and protection against skin cancer development in mice by sunscreens. J. Invest. Dermatol. 112:1999;763-768.
153. Rubinfeld B., Souza B., Albert I.et al. Association of the Apc gene product with β-catenin. Science. 262:1993;1731-1734.
154. Su L.K., Vogelstein B., Kinzler K.W. Association of the Apc tumor suppressor protein with catenins. Science. 262:1993;1734-1737.
155. Shattuck-Brandt R.L., Lamps L.W., Heppner Goss K.J.et al. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol. Carcinogen. 24:1999;177-187.
156. Reich R., Martin G.R. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins. 51:1996;1-17.
157. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3336-3340.
158. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1997;1260-1270.
159. Brueggemeier R.W., Quinn A.L., Parrett M.L.et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 140:1999;27-35.
160. Mayer B., Johnson J.P., Leitl F.et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 53:1993;1690-1695.
161. Shimoyama Y., Hirohashi S. Cadherin intercellular adhesion molecule in hepatocellular carcinomas: loss of E-cadherin expression in an undifferentiated carcinoma. Cancer Lett. 57:1991;131-135.
162. Shiozaki H., Tahara H., Oka H.et al. Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am. J. Pathol. 139:1991;17-23.
163. Sommers C.L., Thompson E.W., Torri J.A.et al. Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Differ. 2:1991;365-372.
164. 2. J. Immunol. 127:1981;121-124.
165. Taffet S., Russell S. Macrophage-mediated tumor cell killing: regulation of expression of cytolytic activity by prostaglandin E. J. Immunol. 126:1981;424-427.
166. Young M., Wheeler E., Newby M. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J. Natl. Cancer Inst. 76:1986;745-750.
167. Swamy M.V., Herzog C.R., Rao C.V. Inhibition of COX-2 in colon cancer cell lines by celecoxib increase the nuclear localization of active p53. Cancer Res. 63:2003;5239-5242.
168. Kakiuchi Y., Tsuji S., Tsujii M.et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res. 62:2002;1567-1572.